Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Operating Income: 2014-2025

Historic Operating Income for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$15.8 million.

  • CytomX Therapeutics' Operating Income fell 483.56% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.2 million, marking a year-over-year increase of 246.44%. This contributed to the annual value of $25.0 million for FY2024, which is 485.49% up from last year.
  • CytomX Therapeutics' Operating Income amounted to -$15.8 million in Q3 2025, which was down 1,126.13% from -$1.3 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Operating Income peaked at $22.6 million during Q1 2025, and registered a low of -$34.9 million during Q4 2021.
  • For the 3-year period, CytomX Therapeutics' Operating Income averaged around $2.2 million, with its median value being -$606,000 (2023).
  • In the last 5 years, CytomX Therapeutics' Operating Income spiked by 3,017.33% in 2024 and then crashed by 483.56% in 2025.
  • CytomX Therapeutics' Operating Income (Quarterly) stood at -$34.9 million in 2021, then spiked by 72.76% to -$9.5 million in 2022, then skyrocketed by 93.63% to -$606,000 in 2023, then surged by 3,017.33% to $17.7 million in 2024, then plummeted by 483.56% to -$15.8 million in 2025.
  • Its Operating Income was -$15.8 million in Q3 2025, compared to -$1.3 million in Q2 2025 and $22.6 million in Q1 2025.